Should adjuvant weekly paclitaxel be considered less efficacious than anthracyclines plus cyclophosphamide for lower-risk patients with early-stage breast cancer?

J Clin Oncol. 2015 Jan 20;33(3):290. doi: 10.1200/JCO.2014.58.7923. Epub 2014 Dec 15.

Authors

Vito Amoroso¹, Rebecca Pedersini², Phoebe Sharratt³, Lucia Vassalli², Laura Ferrari⁴, Sandra Sigala⁵, Edda Simoncini², Alfredo Berruti⁴

Affiliations

¹ University of Brescia at Spedali Civili Hospital, Brescia, Italy vitoamoroso@alice.it.
² Spedali Civili Hospital, Brescia, Italy.
³ Barts and The London School of Medicine and Dentistry, London, United Kingdom.
⁴ University of Brescia at Spedali Civili Hospital, Brescia, Italy.
⁵ University of Brescia, Brescia, Italy.

PMID: 25512451
DOI: 10.1200/JCO.2014.58.7923

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Female
Humans
Paclitaxel / therapeutic use*

Substances

Paclitaxel